New Trends in Brain Shuttle Peptides
Ver/Abrir
Este documento contiene ficheros embargados hasta el dia 03-03-2026
Otros/as autores/as
Fecha de publicación
2025-03-03ISSN
1543-8392
Resumen
The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood–brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from reaching their targets efficiently. However, the BBB allows the passage of nutrients and other molecules that guarantee brain homeostasis through selective transport mechanisms present at the BBB. These mechanisms provide an opportunity for delivering therapeutic agents into the central nervous system using brain shuttles. Here we review the progress of brain shuttle peptide development from 2015 until 2025. We highlight the most utilized peptides and describe trends in strategies to develop new shuttles and enhance their transport efficiency. Additionally, we compared them with other types of brain shuttles and emphasize the progress of peptide shuttles toward clinical translation.
Tipo de documento
Artículo
Versión del documento
Versión aceptada
Lengua
Inglés
Materias (CDU)
615 - Farmacología. Terapéutica. Toxicología. Radiología
616.1 - Patología del sistema circulatorio, de los vasos sanguíneos. Transtornos cardiovasculares
Palabras clave
Blood-brain barrier
Brain shuttle
Drug delivery
Peptide shuttle
Central nervous system therapeutics
Barrera hematoencefàlica
Medicaments--Modes d'administració
Sistema nerviós central--Tractament
Páginas
p.10
Publicado por
American Chemical Society
Publicado en
Molecular Pharmaceutics 2025, 22, 3, 1100–1109
Número del acuerdo de la subvención
info:eu-repo/grantAgreement/MCIU/PN I+D/PID2023-151988OB-I00
Este ítem aparece en la(s) siguiente(s) colección(ones)
Derechos
© L'autor/a